公开(公告)号：US20240263232A1

公开(公告)日：2024-08-08

申请号：US18420361

申请日：2024-01-23

Applicant: BioNTech SE

Inventor： Ugur SAHIN ,  Martin SUCHAN ,  Barbara SCHRÖRS ,  Martin LÖWER ,  Petra OEHM

IPC: C12Q1/6876 ,  C12Q1/686

CPC classification number: C12Q1/6876 ,  C12Q1/686 ,  C12Q2600/156

Abstract: This invention relates to methods for screening for a genotype for loss of antigen presentation via MHC class I in a subject and/or respectively detecting a subject's increased risk of resistance against immunotherapy such as against vaccination.

公开(公告)号：US20230117803A1

公开(公告)日：2023-04-20

申请号：US17759906

申请日：2021-02-02

Applicant: BIONTECH SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Lena KRANZ ,  Mathias VORMEHR

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  A61P37/04 ,  A61P17/00 ,  A61K39/395

Abstract: The present disclosure relates to methods and compositions for inducing an immune response in a subject comprising providing to the subject a peptide or protein vaccine and a binding agent, such as a bispecific antibody, binding to PD-L1 and CD137, such as human PD-L1 and human CD137, e.g., by co-administering to the subject a peptide or protein used for vaccination or a polynucleotide, in particular RNA, encoding a peptide or protein used for vaccination, and a binding agent binding to PD-L1 and CD137 or a polynucleotide, in particular RNA, encoding a binding agent binding to PD-L1 and CD137. The present disclosure further relates to medical preparations useful in the methods disclosed herein.

公开(公告)号：US20230114808A1

公开(公告)日：2023-04-13

申请号：US17310773

申请日：2020-03-11

Applicant: BioNTech SE ,  TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Gemein-N

Inventor： David WEBER ,  Carina WALTER ,  Diana BAREA ROLDAN ,  Ruprecht KUNER ,  Elif DIKEN ,  Martin SUCHAN ,  Stefania GANGI MAURICI ,  Ugur SAHIN

IPC: A61K39/00 ,  A61P35/00 ,  A61P37/04 ,  A61K45/06 ,  A61K39/395 ,  A61K39/39

Abstract: Disclosed herein are compositions, uses, and methods for treatment of prostate cancers. In one aspect, disclosed herein is a composition or medical preparation comprising at least one RNA, wherein the at least one RNA encodes the following amino acid sequences: (i) an amino acid sequence comprising Kallikrein-2 (KLK2), an immunogenic variant thereof, or an immunogenic fragment of the KLK2 or the immunogenic variant thereof; (ii) an amino acid sequence comprising Prostate Specific Antigen (PSA), an immunogenic variant thereof, or an immunogenic fragment of the PSA or the immunogenic variant thereof; (iii) an amino acid sequence comprising Prostatic Acid Phosphatase (PAP), an immunogenic variant thereof, or an immunogenic fragment of the PAP or the immunogenic variant thereof; (iv) an amino acid sequence comprising Homeobox B13 (HOXB13), an immunogenic variant thereof, or an immunogenic fragment of the HOXB13 or the immunogenic variant thereof; and (v) an amino acid sequence comprising NK3 Homeobox 1 (NKX3-1), an immunogenic variant thereof, or an immunogenic fragment of the NKX3-1 or the immunogenic variant thereof.

公开(公告)号：US20220378910A1

公开(公告)日：2022-12-01

申请号：US17854649

申请日：2022-06-30

Applicant: Genentech, Inc. ,  BioNTech SE ,  Hoffmann-La Roche Inc.

Inventor： Lars MUELLER ,  Rachel Lubong SABADO ,  Mahesh YADAV ,  Jingbin ZHANG ,  Ugur SAHIN

IPC: A61K39/395 ,  A61K39/00 ,  A61K9/127 ,  A61P35/00 ,  C07K14/74 ,  C07K14/47 ,  C07H21/04 ,  C07H21/02

Abstract: The present disclosure provides methods for inducing neoepitope-specific CD8+ T cells in an individual or for inducing trafficking of neoepitope-specific CD8+ T cells to a tumor in an individual using an RNA vaccine or using an RNA vaccine in combination with a PD-1 axis binding antagonist. Also provided herein are PD-1 axis binding antagonists and RNA vaccines that include one or more polynucleotides encoding one or more neoepitopes resulting from cancer-specific somatic mutations present in a tumor specimen obtained from the individual for use in methods of inducing neoepitope-specific CD8+ T cells in an individual or for inducing trafficking of neoepitope-specific CD8+ T cells to a tumor in an individual.

公开(公告)号：US20240335511A1

公开(公告)日：2024-10-10

申请号：US18268124

申请日：2021-12-20

Applicant: BioNTech SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Lena Mareen KRANZ ,  Mathias VORMEHR ,  Sina FELLERMEIER-KOPF ,  Jan DIEKMANN ,  David EISEL

IPC: A61K38/20 ,  A61K9/51 ,  A61K38/38 ,  A61K48/00 ,  A61P35/00 ,  C07K14/54 ,  C07K14/55 ,  C07K14/765

CPC classification number: A61K38/2046 ,  A61K9/5146 ,  A61K38/2013 ,  A61K38/38 ,  A61K48/0041 ,  A61P35/00 ,  C07K14/5418 ,  C07K14/55 ,  C07K14/765 ,  C07K2319/31

Abstract: This disclosure relates to the field of therapeutic RNA to treat cancer, in particular advanced solid tumors such as metastatic (Stage IV) or unresectable localized cancer. Disclosed herein are compositions, uses, and methods for treatment of cancers. Administration of therapeutic RNAs to a patient having cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.

公开(公告)号：US20230145774A1

公开(公告)日：2023-05-11

申请号：US17907013

申请日：2021-03-30

Applicant: BIONTECH SE ,  TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ

Inventor： Ugur SAHIN ,  Lena Mareen KRANZ ,  Mustafa DIKEN ,  Lina HILSCHER ,  Sebastian KREITER

IPC: A61K39/00 ,  A61K39/39 ,  A61P37/02

CPC classification number: A61K39/0011 ,  A61K39/39 ,  A61P37/02 ,  A61K2039/55561 ,  A61K2039/55538 ,  A61K2039/55527 ,  A61K2039/55522

Abstract: The present disclosure relates to methods and agents for antigen vaccination and inducing effective antigen-specific immune effector cell responses such as T cell responses. Specifically, the present disclosure relates to methods comprising administering to a subject (i) non-immunogenic RNA encoding a peptide or protein comprising an epitope for inducing an immune response against an antigen in the subject, i.e., non-immunogenic RNA encoding vaccine antigen; and (ii) an immunostimulant or RNA encoding an immunostimulant. Administering to the subject non-immunogenic RNA encoding vaccine antigen may provide (following expression of the RNA by appropriate target cells) vaccine antigen for stimulation, priming and/or expansion of immune effector cells and, thus, may induce an immune response against vaccine antigen (and disease-associated antigen) in the subject.

公开(公告)号：US20250025505A1

公开(公告)日：2025-01-23

申请号：US18717782

申请日：2022-12-08

Applicant: BioNTech SE

Inventor： Ugur SAHIN ,  Petra OEHM ,  Benjamin RENGSTL ,  Katharina REINHARD ,  Liane Monika PREUSSNER ,  Özlem TÜRECI

IPC: A61K35/17 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7105 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0783

Abstract: The present disclosure relates to chimeric antigen receptor (CAR) expressing immune effector cells showing highly specific and sensitive recognition of CLDN6 expressing cancer cells as well as a high potential for treating cancer in humans.

公开(公告)号：US20240415946A1

公开(公告)日：2024-12-19

申请号：US18699937

申请日：2022-10-10

Applicant: BIONTECH SE ,  TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBE

Inventor： Ugur SAHIN ,  David WEBER ,  Carina WALTER ,  Diana BAREA ROLDÁN ,  Ruprecht KUNER ,  Melanie HEIN ,  Martin SUCHAN, ,  Vetena KISSLER ,  Lena Mareen KRANZ

IPC: A61K39/00 ,  A61K9/00 ,  A61K9/127 ,  A61P35/00

Abstract: This disclosure relates to the field of RNA to treat lung cancer, in particular non-small-cell lung carcinoma (NSCLC). Lung cancer is the third most frequent malignancy in women and the second most frequent malignancy in men. NSCLC accounts for about 85% of all lung cancers. Disclosed herein are compositions, uses, and methods for treatment of lung cancers. Administration of therapeutic RNAs to a patient having lung cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.

公开(公告)号：US20240415828A1

公开(公告)日：2024-12-19

申请号：US18704537

申请日：2022-11-09

Applicant: BIONTECH SE

Inventor： Ugur SAHIN ,  Hariz Iskandar Bin HASSAN ,  Stefan STROBL ,  Roman RÖSEMANN

IPC: A61K31/4745 ,  A61K9/00 ,  A61K31/555 ,  A61K31/7048 ,  A61K39/00 ,  A61P35/00 ,  C07D471/04 ,  C07K16/28

Abstract: The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, in particular a solid cancer.

公开(公告)号：US20240009238A1

公开(公告)日：2024-01-11

申请号：US18044955

申请日：2021-09-14

Applicant: BioNTech SE

Inventor： Ugur SAHIN ,  Joycelyn WÜSTEHUBE-LAUSCH ,  Hans-Ulrich SCHMOLDT

IPC: A61K35/17 ,  C07K16/28 ,  C12N5/0783 ,  A61K39/00 ,  A61P35/00

CPC classification number: A61K35/17 ,  C07K16/28 ,  C12N5/0636 ,  A61K39/4633 ,  A61K39/4611 ,  A61P35/00 ,  A61K39/464402 ,  A61K2239/13

Abstract: The invention relates to agents and methods for targeted delivery of payloads to cells. The agents and methods are useful for delivering therapeutic or diagnostic agents to target cells. In one embodiment, the invention involves administering RNA encoding a peptide or polypeptide (docketing compound) comprising a binding moiety (primary targeting moiety) binding to target cells and a further binding moiety (secondary target) binding to an agent that comprises a payload (effector probe). Following expression of the RNA, the primary targeting moiety may bind to a target antigen such as a cancer antigen on cancer cells and then a secondary targeting moiety comprised in the effector probe may target the secondary target to thereby precisely deliver a “payload” to the target cells such as cancer cells.